HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214
Belite Bio, Inc. ADR
Belite Bio, Inc. ADR BLTE | 0.00 |
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:
BLTE) with a Buy and raises the price target from $200 to $214.
